Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a key pathway in the peripheral nervous system.
SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Eli Lilly is paying $40 million up front for rights to a Confo Therapeutics drug in Phase 1 testing as a potential treatment for neuropathic pain. Confo develops drugs that target G-protein coupled receptors.
Collegium Pharmaceutical’s acquisition of BioDelivery Sciences International brings a pain drug that’s administered in a different way than its current lineup of medicines. The deal also gives Collegium a way to break into the neurology market.
The companies will test Biofourmis' sensor and artificial intelligence system in a clinical trial of more than 120 women with endometriosis.
The US-based subsidiary will bring together existing research and development and manufacturing businesses in the US, India and Switzerland.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
The company plans to use the financing to support development of its drug, KarXT, in schizophrenia and indications like pain.
The Digital Health Breakthrough Network, which is a partnership between HITLAB and NYCEDC, recently announced its third cohort of startups. The class includes Altopax, Navimize, PainQx and Tatch.
Philadelphia startup PainQx has software that uses EEG data to objectively measure pain in patients. The current system of measuring pain is, after all, rudimentary at best.